Any current/future new fundraising through debt or equity?

No major capital expenditure is planned for FY '24; the company intends to fund maintenance capex (~INR 20-30 crores) through internal accruals. For working capital, an initial requirement of INR 20-30 crores is expected in the first half of FY '24, which will taper down by year-end. The company holds a USD 15 million FCCB (Foreign Currency Convertible Bond) option with IFC, likely to be converted at INR 105 crores, which would reduce debt by around INR 115-120 crores. No specific mention of new fundraising through fresh debt or equity was made during the call. Overall, operational cash flows

Any current/future capex/capital investment/strategic investment?

No major capex planned for FY '24; focus on utilizing internal accruals for maintenance capex (~INR 20-30 crores per annum). Working capital requirement may increase by INR 20-30 crores in the first 6 months but expected to taper off by year-end FY '24. Discussions in FY '24 about potentially building a new plant to meet demand beyond current capacity (~800 tons/year). Expansion priorities in next 2-3 years include growing diphenol downstream products, Aroma business (vanillin, heliotropin), blend business (natural products), and scaling up Omega-3 fatty acid business. Vanillin plant commissio

Future growth expectations in sales/revenue/volumes?

Expecting revenue growth of about 25% per year over the next few years (Page 14). FY '24 projected to see growth in revenue around 30% to 35% compared to FY '23 (Page 4, 11). Volume growth expected despite price corrections and softer chemical prices (Page 13). Vanillin plant ramp-up: gradual scaling with commercial realization starting Q1 FY '24; full market penetration over two years (Page 10-11, 15). Targeting at least 50% global market share in MEHQ in the next 2 years, with other HQ downstream products also scaling up (Page 12-13). Continued growth in blend business at about 30%

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects revenue growth of about 25-35% annually for FY 2024 and FY 2025. EBITDA margins are projected to expand, driven by scaling up vanillin production and improved yields/processes. Vanillin plant ramp-up to 100% production by end of FY 2023, contributing margin accretive revenues starting FY 2024. Growth drivers also include increased focus on HQ downstream products like MEHQ, HQEE, para-benzoquinone, and naphthol IRG from FY 2024 onwards. Internal cost mitigation programs aim to reduce fixed operating costs by 20%, aiding margin improvement. No major capex planned im

Current/ Expected Orderbook/ Pending Orders?

The company has new orders lining up from Q2 FY '24 onwards, indicating an expected increase in order inflow. For Lockheed Martin, the first commercial order is on track for delivery by Q2 FY '24, with further orders under discussion contingent upon product market success. The capacities, especially for Lockheed Martin order, are limited right now (around 800 tons/year), expected to fill up by FY '25, prompting discussions for potential new plant construction during FY '24. Vanillin is in the sampling phase, with supply expected to start before the end of FY '23 and real production ramping up

Camlin Fine Sciences LtdQ3 FY23Chemicals & Petrochemicals

Camlin Fine Sciences Ltd Q3 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹82.32Market Cap: ₹1.6K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 2

Expecting revenue growth of about 25% per year over the next few years (Page 14).
FY '24 projected to see growth in revenue around 30% to 35% compared to FY '23 (Page 4, 11).
Volume growth expected despite price corrections and softer chemical prices (Page 13).
Vanillin plant ramp-up: gradual scaling with commercial realization starting Q1 FY '24; full market penetration over two years (Page 10-11, 15).
Targeting at least 50% global market share in MEHQ in the next 2 years, with other HQ downstream products also scaling up (Page 12-13).
Continued growth in blend business at about 30% per year (Page 5).
Opportunities in specialty natural products and Omega 3 fatty acids expansion planned in next 3-4 years (Page 5).
Capacity constraints likely to be addressed in FY '24 with discussions for next plant building underway (Page 14).

Margin guidance

Category 1

The company expects revenue growth of about 25-35% annually for FY 2024 and FY 2025.
EBITDA margins are projected to expand, driven by scaling up vanillin production and improved yields/processes.
Vanillin plant ramp-up to 100% production by end of FY 2023, contributing margin accretive revenues starting FY 2024.
Growth drivers also include increased focus on HQ downstream products like MEHQ, HQEE, para-benzoquinone, and naphthol IRG from FY 2024 onwards.
Internal cost mitigation programs aim to reduce fixed operating costs by 20%, aiding margin improvement.
No major capex planned immediately; expansion to be funded via internal accruals.
Lockheed Martin order post FY 2024 could contribute significantly (over 10-15% of business) depending on market success.
Despite market price corrections, volume growth and new products expected to sustain profit growth.

See what Camlin Fine Sciences Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

No major capital expenditure is planned for FY '24; the company intends to fund maintenance capex (~INR 20-30 crores) through internal accruals.
For working capital, an initial requirement of INR 20-30 crores is expected in the first half of FY '24, which will taper down by year-end.
The company holds a USD 15 million FCCB (Foreign Currency Convertible Bond) option with IFC, likely to be converted at INR 105 crores, which would reduce debt by around INR 115-120 crores.
No specific mention of new fundraising through fresh debt or equity was made during the call.
Overall, operational cash flows are expected to improve, supporting debt reduction without the need for significant external borrowing or equity issuance in FY '24.

Order book

The company has new orders lining up from Q2 FY '24 onwards, indicating an expected increase in order inflow.
For Lockheed Martin, the first commercial order is on track for delivery by Q2 FY '24, with further orders under discussion contingent upon product market success.
The capacities, especially for Lockheed Martin order, are limited right now (around 800 tons/year), expected to fill up by FY '25, prompting discussions for potential new plant construction during FY '24.
Vanillin is in the sampling phase, with supply expected to start before the end of FY '23 and real production ramping up from Q1 FY '24.
MEHQ and other downstream products like HQEE, para-benzoquinone, and naphthol IRG are areas of focus for growth, with increasing production planned within available and identified capacities.
The management expects substantial traction in these product lines in FY '24 and FY '25.

See what Camlin Fine Sciences Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

No major capex planned for FY '24; focus on utilizing internal accruals for maintenance capex (~INR 20-30 crores per annum).
Working capital requirement may increase by INR 20-30 crores in the first 6 months but expected to taper off by year-end FY '24.
Discussions in FY '24 about potentially building a new plant to meet demand beyond current capacity (~800 tons/year).
Expansion priorities in next 2-3 years include growing diphenol downstream products, Aroma business (vanillin, heliotropin), blend business (natural products), and scaling up Omega-3 fatty acid business.
Vanillin plant commissioned and ramping up; expected to reach near 100% capacity by end of FY '23 but market demand will dictate actual production.
Growth driven more by capacity utilization and market demand than new large-capex initiatives currently.

Track Camlin Fine Sciences Ltd — get its next earnings analysis in your feed

How does Camlin Fine Sciences Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

ThisCamlin Fine Sciences Ltd

Rev 2Mar 1

See where Camlin Fine Sciences Ltd sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Camlin Fine Sciences Ltd rank in Chemicals & Petrochemicals?

Compare Camlin Fine Sciences Ltd against every Chemicals & Petrochemicals company (Q3 FY23) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

What Camlin Fine Sciences Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

POCL Enterprises Ltd (Q1 FY27)
466.03 crores (Page 12, 17, 11) . Key investor presentation takeaways from POCL Enterprises Ltd's Q1 FY27 investor presentation — and how it ranks against secto
Deepak Nitrite Ltd (Q2 FY27)
Q2 FY27 total revenue: ₹3,091 crore, up 61% YoY (Page 1, 4, 5, 6, 10, 11) . Key investor presentation takeaways from Deepak Nitrite Ltd's Q2 FY27 investor prese
Privi Speciality Chemicals Ltd (Q2 FY27)
19,239.47 lakhs (approximately 33.9% growth). Key results statement takeaways from Privi Speciality Chemicals Ltd's Q2 FY27 results statement — and how it ranks
NOCIL Ltd (Q2 FY27)
427 crores . Key investor presentation takeaways from NOCIL Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.

Compare:vs Solar Industries vs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →